Day: March 2, 2022

NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of 2022 WEST CHESTER, Pa., March 02, 2022 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2021. “2022 is poised to be an exciting year for Verrica as we prepare to potentially launch VP-102 this summer for the treatment of molluscum, a disease affecting an estimated six million patients with no approved treatments, representing a significant market opportunity,” said Ted White, Verrica’s President and Chief Executive Officer....

– Q4 2021 Net Income of $10.6 Million, or $1.40 per Diluted Share – – Full Year 2021 Net Income of $38.1 Million, or $5.00 per Diluted Share – – Board of Directors Authorizes New $75 Million Share Repurchase Program Over Two Years – VANCOUVER, Washington, March 02, 2022 (GLOBE NEWSWIRE) — Barrett Business Services, Inc. (“BBSI” or the “Company”) (NASDAQ: BBSI), a leading provider of business management solutions, reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Financial Summary vs. Year-Ago QuarterNet revenues up 10% to $256.6 million. Gross billings up 13% to $1.81 billion. Average worksite employees (“WSEs”) up 7%. Net income of $10.6 million, or $1.40 per diluted share, compared to $7.2 million, or $0.93 per diluted share.Full...

Total Fiscal Year Revenue Increases 19% Year-Over-Year, Driven by 23% Year-over-Year Growth in Identity RFID Unit Shipments Up 36% Year-Over-Year to Record 185 Million Units FREMONT, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Identiv, Inc. (NASDAQ: INVE), a global leader in digital security and identification in the Internet of Things (IoT), reported financial results for the fourth quarter and fiscal year ended December 31, 2021, achieving several operational and financial milestones in 2021 that strengthen the company’s foundation for future growth. Full Year 2021, Fourth Quarter 2021 and Recent Financial and Operational HighlightsTotal full year 2021 revenue grew 19% year-over-year to a record $103.8 million. Fourth quarter revenue grew 15% year-over-year to $28.5 million. 2021 Identity revenue grew 23% year-over-year; Premises...

BILLERICA, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 SummaryFinalized commercial launch activities for our new Image-to-Implant® Platinum Services℠ Program, a premium service offering for the U.S. market. Total revenue of $15.4 million, a decrease of 8% year-over-year on a reported and constant currency basis. Product revenue of $15.3 million, a decrease of 8% year-over-year on a reported and constant currency basis. Conformis hip system revenue up 8% year-over-year to $0.7 million. Cash and cash equivalents of $100.6 million as of December 31, 2021. Refinanced our existing senior secured indebtedness...

Active customers up 50% year over yearSend volume up 64% year over yearRevenue up 69% year over year SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) — Remitly Global, Inc. (NASDAQ: RELY), a leading digital financial services provider for immigrants and their families in over 150 countries around the world, reported results for the fourth quarter and full year ended December 31, 2021. “Reflecting on our strong fourth quarter growth, I’m incredibly proud of all that Remitly delivered and am reminded of the significance of the work we’re doing to transform the lives of our customers,” said Matt Oppenheimer, Remitly’s Chief Executive Officer. “Looking ahead, we’re excited to drive new customer growth, geographic expansion, and new product development through strategic investments in the business. These outcomes will create enduring value...

Fourth Quarter 2021 Revenue Increased 31% Year-over-Year2021 Revenue Increased 38% Year-over-Year WARSAW, Ind., March 02, 2022 (GLOBE NEWSWIRE) —  OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today its financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Business Highlights      Helped an estimated 9,500 children in the fourth quarter 2021 and record 38,000 for full year 2021, bringing the total to more than 234,000 children since the inception of OrthoPediatrics Generated total revenue of $24.8 million for fourth quarter 2021, up 31% from $18.9 million in fourth quarter 2020; domestic revenue increased 11% and international revenue increased 363% in the quarter Generated...

Company to Host Conference Call at 8:30 AM ET on Thursday, March 3, 2022 BIRMINGHAM, Mich., March 02, 2022 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights (compared to the prior year period)Gross written premium increased 14.5% to $33.0 million Net earned premiums increased 13.4% to $26.2 million Loss ratio improved by 420 basis points to 62.5%Year End 2021 Financial Highlights (compared to the prior year period)Gross written premium increased 18.6% to $132.1 million Net earned premium increased 10.9% to $98.8 million, driving expense ratio improvement Net loss of $1.1 million, or $0.11 per share, based on 9.7 million average shares outstanding Book value per share...

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) — Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and year ended December 31, 2021. Business Update We are pleased to report another strong quarter and year of financial results for Silvercrest, with new high earnings marks. The firm’s discretionary assets under management (“AUM”), which drive revenue, increased by $2.6 billion, or 11.6%, during the fourth quarter of 2021, to $25.1 billion as of December 31, 2021. For the full year 2021, discretionary AUM increased by $4.5 billion, or 21.8%, to $25.1 billion as of December 31, 2021. The firm’s total AUM concluded the quarter and the year at $32.3 billion, up 16.2% and 4.2% for the year and during the fourth quarter, respectively....

– Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter – Demand for SKYTROFA® (lonapegsomatropin-tcgd), the only FDA-approved once-weekly somatropin, continues to grow in the U.S. – Conference call today at 4:30 pm ET COPENHAGEN, Denmark, March 02, 2022 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the full year ended December 31, 2021 and provided a business update. “2021 was an extraordinary year for Ascendis, and we expect that 2022 will be even stronger. The regulatory approvals of TransCon hGH in the U.S. and Europe were key milestones in achieving our Vision 3×3,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief...